⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 22, 2025ADC Review / Journal of Antibody-drug ConjugatesOpen Access

Can Precision ADC Therapy Overcome Current Barriers in AML?

M. R. Müller Lisa Ivanschitz

View Full Paper

Ask AI

Bookmark

Share

Key Points

Current AML treatments often yield poor prognosis, with overall survival typically under one year.
Hypomethylating agents like azacitidine and decitabine show improved response rates but are insufficient for many patients.
Older or unfit AML patients face significant challenges due to limited treatment options available to them.
Precision ADC therapy may provide a promising alternative to existing therapies in treating AML effectively.

Implication

Analysis reveals precision ADC therapy may improve outcomes in older AML patients, suggesting new strategies are needed.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Müller et al. (2025) studied this question.

synapsesocial.com/papers/68d473b531b076d99fa6c663 https://doi.org/10.14229/jadc.2025.09.19.001

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1New Therapeutic Approaches for Acute Myeloid LeukaemiaHuman Clinical Trial · 2021 · 1 citations
2Targeted Therapy in Acute Myeloid Leukemia: Current Approaches and Novel DirectionsOriginal Research · 2026 · 1 citations
3Navigating the Landscape of Antibody Drug Conjugates: Current Trends and Future Research Prospects in Acute Myeloid LeukemiaClinical Trial · 2026 · 1 citations
4Transforming Acute Myeloid Leukemia Care Through Precision Medicine: Integrating Genomic Profiling, Measurable Residual Disease, and Targeted TherapiesNarrative Review · 2026
5Integrating Targeted Therapies into AML Frontline Therapy: Who Gets What and What Does the Future Hold?Human Clinical Trial · 2026

More related papers

Targeted Therapies Combined with Intensive Chemotherapy in Fit Acute Myeloid Leukemia: Past Developments, Current Evidence, and Future Therapeutic Paradigms2026
Evolving Paradigms in Acute Myeloid Leukemia: Personalized Approaches to Therapy Across Age and Risk Groups2025
Latest Insights and Progress in the Clinical Management of Elderly Patients with Acute Myeloid Leukemia: From Genetic Advancements to Targeted Treatments2024

More from ADC Review / Journal of Antibody-drug Conjugates

NICE Approves Enfortumab Vedotin + Pembrolizumab as First-line Treatment for Adults with Metastatic Urothelial Cancer in the UKFri,
NICE Approves Enfortumab Vedotin + Pembrolizumab as First-line Treatment for Adults with Metastatic Urothelial Cancer in the UKFri,